Olaf StÃ¼ve

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2619292/publications.pdf

Version: 2024-02-01

181 papers	12,552 citations	28274 55 h-index	25787 108 g-index
186 all docs	186 docs citations	186 times ranked	12103 citing authors

#	Article	IF	Citations
1	To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England. Multiple Sclerosis and Related Disorders, 2022, 59, 103541.	2.0	1
2	Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure. Frontiers in Neurology, 2022, 13, 854390.	2.4	9
3	Cognitive Decline in Older People with Multiple Sclerosisâ€"A Narrative Review of the Literature. Geriatrics (Switzerland), 2022, 7, 61.	1.7	2
4	Utilization of a neurology specialty service by primary care providers for headache management at a tertiary care hospital. Journal of Central Nervous System Disease, 2022, 14, 117957352211131.	1.9	0
5	Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database. Multiple Sclerosis Journal, 2021, 27, 1066-1076.	3.0	26
6	Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199050.	3.5	5
7	Persistent severe lymphopenia 5â€‰years after dimethyl fumarate discontinuation. Multiple Sclerosis Journal, 2021, 27, 1306-1308.	3.0	6
8	Systems Approaches to Unravel T Cell Function and Therapeutic Potential in Autoimmune Disease. Journal of Immunology, 2021, 206, 669-675.	0.8	2
9	CD11c⁺CD88⁺CD317⁺myeloid cells are critical mediators of persistent CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	11
10	The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo. Journal of Neuroimmunology, 2021, 354, 577544.	2.3	0
11	Apolipoprotein E receptor 2 deficiency decreases endothelial adhesion of monocytes and protects against autoimmune encephalomyelitis. Science Immunology, 2021, 6, .	11.9	8
12	Choroid plexus volumetrics and brain inflammation in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	34
13	Disease-modifying therapy prescription patterns in people with multiple sclerosis by age. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110064.	3.5	11
14	Biological Significance of Antiâ€"SARS-CoV-2 Antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	2
15	Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report. Journal of Central Nervous System Disease, 2021, 13, 117957352110537.	1.9	1
16	The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 876-886.	3.0	41
17	Natalizumab wearing-off effect. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e706.	6.0	2
18	Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096901.	3.5	20

#	Article	IF	Citations
19	Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?. Frontiers in Neurology, 2020, 11, 607766.	2.4	22
20	Reelin depletion protects against autoimmune encephalomyelitis by decreasing vascular adhesion of leukocytes. Science Translational Medicine, 2020, 12, .	12.4	14
21	Limitations of cell-lineage-specific non-dynamic gene recombination in CD11c.Cre+ITGA4fl/fl mice. Journal of Neuroimmunology, 2020, 344, 577245.	2.3	5
22	Diclofenac reduces the risk of Alzheimerâ€™s disease: a pilot analysis of NSAIDs in two US veteran populations. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093567.	3.5	27
23	Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients. PLoS ONE, 2020, 15, e0228617.	2.5	16
24	Trials and therapies in secondary progressive MS, simplified. Nature Reviews Neurology, 2019, 15, 431-432.	10.1	7
25	Immunological Aspects of Approved MS Therapeutics. Frontiers in Immunology, 2019, 10, 1564.	4.8	117
26	Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641985498.	3.5	76
27	MAdCAM-1-Mediated Intestinal Lymphocyte Homing Is Critical for the Development of Active Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2019, 10, 903.	4.8	17
28	Clinical trials in multiple sclerosis: potential future trial designs. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984709.	3.5	10
29	Î±4-integrin deficiency in B cells does not affect disease in a T-cellâ€“mediated EAE disease model. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e563.	6.0	9
30	Evolution of clinical trials in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641982654.	3.5	37
31	Neurofilament light chain. Neurology, 2019, 92, 451-452.	1.1	16
32	Simplification of combination antiretroviral therapy (cART) and the brainâ€”a real-life experience. Journal of NeuroVirology, 2019, 25, 174-182.	2.1	8
33	The role of B cells in multiple sclerosis: Current and future therapies. Cellular Immunology, 2019, 339, 10-23.	3.0	29
34	Natalizumab: Perspectives from the Bench to Bedside. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a029066.	6.2	11
35	Emerging drugs for primary progressive multiple sclerosis. Expert Opinion on Emerging Drugs, 2018, 23, 97-110.	2.4	10
36	B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641876169.	3.5	67

#	Article	IF	Citations
37	Similar Biophysical Abnormalities in Glomeruli and Podocytes from Two Distinct Models. Journal of the American Society of Nephrology: JASN, 2018, 29, 1501-1512.	6.1	23
38	Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e437.	6.0	11
39	Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating Î²7+ T Cells in Crohnâ€™s Disease: Report of the TOSCA Study. Journal of Crohn's and Colitis, 2018, 12, 188-196.	1.3	24
40	WED 183â€...Cladribine tablets effects on t cell subsets in patients with early ms. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A25.2-A25.	1.9	0
41	<scp>TLR</scp>3 agonism reâ€establishes <scp>CNS</scp> immune competence during Î±4â€integrin deficiency. Annals of Clinical and Translational Neurology, 2018, 5, 1543-1561.	3.7	8
42	WED 186â€...Effect of cladribine tablets on immune cells in patients with ms. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A26.2-A26.	1.9	0
43	Clinical trials in multiple sclerosis: milestones. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878549.	3.5	7
44	PDCB does not promote CNS autoimmunity in the context of genetic susceptibility but worsens its outcome. Journal of Neuroimmunology, 2018, 323, 53-55.	2.3	1
45	Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis. PLoS ONE, 2018, 13, e0200752.	2.5	4
46	Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology. Journal of Immunology, 2017, 198, 1381-1386.	0.8	21
47	Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease. Journal of Neuroimmunology, 2017, 309, 100-110.	2.3	5
48	The major histocompatibility complex and antibodyâ€mediated limbic encephalitis. Annals of Neurology, 2017, 81, 181-182.	5.3	1
49	Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project. Journal of the American College of Radiology, 2017, 14, 371-379.e1.	1.8	49
50	Normal intrathecal leukocyte cell number and composition do not decrease the incidence of postâ€“lumbar puncture headache. Journal of Neuroimmunology, 2017, 310, 69-71.	2.3	1
51	B-cellâ€“targeted therapies in relapsing forms of MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e405.	6.0	10
52	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	7.6	139
53	Spotlight on daclizumab: its potential in the treatment of multiple sclerosis. Degenerative Neurological and Neuromuscular Disease, 2016, Volume 6, 95-109.	1.3	2
54	Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis. Current Opinion in Neurology, 2016, 29, 278-285.	3.6	16

#	Article	IF	Citations
55	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2016, 73, 1089.	9.0	92
56	Targeting â€œbadâ€•B cells in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e283.	6.0	0
57	Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of â€˜Chinese restaurant syndromeâ€™. Journal of Neurology, 2016, 263, 1027-1028.	3.6	2
58	Managing Disability in Progressive Multiple Sclerosis. Current Treatment Options in Neurology, 2016, 18, 27.	1.8	8
59	Diagnostic and therapeutic strategies for management of autoimmune encephalopathies. Expert Review of Neurotherapeutics, 2016, 16, 937-949.	2.8	29
60	Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics, 2016, 16, 1131-1139.	2.8	17
61	Primary progressive multiple sclerosisâ€”why we are failing. Lancet, The, 2016, 387, 1032-1034.	13.7	12
62	Acute relapse after initiation of Siponimod in a patient with secondary progressive MS. Journal of Neurology, 2016, 263, 606-610.	3.6	6
63	B cell-directed therapies in multiple sclerosis. Neurodegenerative Disease Management, 2016, 6, 37-47.	2.2	30
64	Will Biomarkers Determine What Is Next in Multiple Sclerosis?. JAMA Neurology, 2016, 73, 496.	9.0	4
65	Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis. Neurotherapeutics, 2016, 13, 58-69.	4.4	69
66	A Single Amino Acid Substitution Prevents Recognition of a Dominant Human Aquaporin-4 Determinant in the Context of HLA-DRB1*03:01 by a Murine TCR. PLoS ONE, 2016, 11, e0152720.	2.5	7
67	IL-12/IL-23p40 Is Highly Expressed in Secondary Lymphoid Organs and the CNS during All Stages of EAE, but Its Deletion Does Not Affect Disease Perpetuation. PLoS ONE, 2016, 11, e0165248.	2.5	7
68	Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab. Neuropsychiatric Disease and Treatment, 2015, 11, 2405.	2.2	10
69	Treatment Decisions for Patients With Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 387.	9.0	3
70	Natalizumab to fingolimod. Neurology, 2015, 85, 14-15.	1.1	2
71	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 815.	9.0	59
72	Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert Review of Clinical Immunology, 2015, 11, 93-108.	3.0	16

#	Article	IF	Citations
73	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Multiple Sclerosis Journal, 2015, 21, 263-281.	3.0	273
74	The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 305-317.	3.0	381
75	Dimethyl fumarate in relapsingâ€“remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Review of Neurotherapeutics, 2015, 15, 339-346.	2.8	69
76	High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS). JAMA Neurology, 2015, 72, 159.	9.0	158
77	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 332-341.	3.0	39
78	Multiple sclerosis drugs: how much bang for the buck?. Lancet Neurology, The, 2015, 14, 460-461.	10.2	4
79	Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis â€“ an observational study. European Journal of Clinical Investigation, 2015, 45, 587-593.	3.4	17
80	B lymphocytes in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e104.	6.0	132
81	The spectrum of autoimmune encephalopathies. Journal of Neuroimmunology, 2015, 287, 93-97.	2.3	46
82	Smoking Beyond Multiple Sclerosis Diagnosis. JAMA Neurology, 2015, 72, 1105.	9.0	0
83	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 282-293.	3.0	131
84	A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 294-304.	3.0	79
85	A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 342-349.	3.0	100
86	A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 318-331.	3.0	131
87	Isoniazid in autoimmunity: a trigger for multiple sclerosis?. Therapeutic Advances in Neurological Disorders, 2014, 7, 253-256.	3.5	7
88	Multiple Sclerosis Disease Progression and Paradichlorobenzene. JAMA Neurology, 2014, 71, 228.	9.0	8
89	The genetics of natalizumab hypersensitivity. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e52.	6.0	2
90	Para-dichlorobenzene toxicity â€“ a review of potential neurotoxic manifestations. Therapeutic Advances in Neurological Disorders, 2014, 7, 177-187.	3.5	25

#	Article	IF	Citations
91	Immunopathogenesis of Neuromyelitis Optica. Advances in Immunology, 2014, 121, 213-242.	2.2	55
92	Heat exposure and bicycling trigger recurrent aseptic meningitis: a case report. BMC Neurology, 2014, 14, 230.	1.8	1
93	Does Natalizumab Therapy Benefit Patients With Multiple Sclerosis?. JAMA Neurology, 2014, 71, 945.	9.0	3
94	Immunophenotyping of Cerebrospinal Fluid Cells in Multiple Sclerosis. JAMA Neurology, 2014, 71, 905.	9.0	54
95	Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance. Journal of Neuroimmunology, 2014, 276, 232-235.	2.3	0
96	Natalizumab to fingolimodâ€"the washout whitewash. Nature Reviews Neurology, 2014, 10, 311-313.	10.1	7
97	Immune surveillance of the central nervous system in multiple sclerosis â€" Relevance for therapy and experimental models. Journal of Neuroimmunology, 2014, 276, 9-17.	2.3	30
98	Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?. Multiple Sclerosis Journal, 2014, 20, 1304-1305.	3.0	53
99	CD19 as a molecular target in CNS autoimmunity. Acta Neuropathologica, 2014, 128, 177-190.	7.7	22
100	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.1	2,344
101	Alemtuzumab. Neurology, 2014, 83, 87-97.	1.1	52
102	The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2013, 10, 67.	7.2	12
103	Management of Secondary Progressive Multiple Sclerosis: Prophylactic Treatmentâ€"Past, Present, and Future Aspects. Current Treatment Options in Neurology, 2013, 15, 241-258.	1.8	24
104	Progressive multiple sclerosis: desperately seeking remedy. Lancet Neurology, The, 2013, 12, 840-841.	10.2	2
105	A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Multiple Sclerosis Journal, 2013, 19, 59-68.	3.0	21
106	Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica. JAMA Neurology, 2013, 70, 390.	9.0	112
107	The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nature Reviews Neurology, 2013, 9, 267-276.	10.1	181
108	Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. European Journal of Immunology, 2013, 43, 2078-2088.	2.9	18

#	Article	IF	Citations
109	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurology, The, 2013, 12, 756-767.	10.2	205
110	A bird's-eye view of T cells during natalizumab therapy. Neurology, 2013, 81, 1372-1373.	1.1	3
111	Human Aquaporin 4₂₈₁₋₃₀₀Is the Immunodominant Linear Determinant in the Context of HLA-DRB1*03:01. Archives of Neurology, 2012, 69, 1125-31.	4.5	16
112	Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects. Current Pharmaceutical Design, 2012, 18, 209-219.	1.9	48
113	From injection therapies to natalizumab: views on the treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2012, 5, 97-104.	3.5	6
114	Firategrastâ€"natalizumab in a pill?. Lancet Neurology, The, 2012, 11, 120-121.	10.2	4
115	Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: 2-Year Follow-up Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI). Blood, 2012, 120, 962-962.	1.4	0
116	A critical appraisal of treatment decisions in multiple sclerosisâ€"old versus new. Nature Reviews Neurology, 2011, 7, 255-262.	10.1	64
117	Rituximab Therapy Reduces Organ-Specific T Cell Responses and Ameliorates Experimental Autoimmune Encephalomyelitis. PLoS ONE, 2011, 6, e17103.	2.5	69
118	Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices. Current Neuropharmacology, 2011, 9, 417-428.	2.9	47
119	The increasing incidence and prevalence of female multiple sclerosisâ€"A critical analysis of potential environmental factors. Autoimmunity Reviews, 2011, 10, 495-502.	5.8	174
120	Lymph node-derived donor encephalitogenic CD4+T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet. Journal of Neuroinflammation, 2011, 8, 73.	7.2	33
121	Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: Early Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI). Blood, 2011, 118, 3075-3075.	1.4	2
122	Anticipated benefits and surprising effects of daclizumab in multiple sclerosis. Lancet Neurology, The, 2010, 9, 337-338.	10.2	6
123	Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. Journal of Neuroimmunology, 2010, 219, 1-7.	2.3	82
124	Memory B cells from a subset of treatmentâ€naÃ¯ve relapsingâ€remitting multiple sclerosis patients elicit CD4⁺ Tâ€cell proliferation and IFNâ€Î³ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. European Journal of Immunology, 2010, 40, 2942-2956.	2.9	114
125	Natalizumab and Progressive Multifocal Leukoencephalopathy. Archives of Neurology, 2010, 67, 923-30.	4.5	105
126	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 15-28.	3.5	29

#	Article	IF	Citations
127	Translational Research in Neurology and Neuroscience 2010. Archives of Neurology, 2010, 67, 1307-15.	4.5	11
128	The Combination of Interferonâ€Beta and HMGâ€CoA Reductase Inhibition in Multiple Sclerosis: Enthusiasm Lost too Soon?. CNS Neuroscience and Therapeutics, 2010, 16, 362-373.	3.9	26
129	Multiple Sclerosis in the Elderly Patient. Drugs and Aging, 2010, 27, 283-294.	2.7	55
130	Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Therapeutic Advances in Neurological Disorders, 2009, 2, 357-368.	3.5	57
131	Primary central nervous system lymphoma in a patient treated with natalizumab. Annals of Neurology, 2009, 66, 403-406.	5.3	78
132	Is 1+1 0, 1, 2, or 11? Arithmetics of antiinflammatory agents in autoimmunity. Experimental Neurology, 2009, 217, 4-6.	4.1	1
133	Direct and consensual murine pupillary reflex metrics: Establishing normative values. Autonomic Neuroscience: Basic and Clinical, 2009, 151, 164-167.	2.8	19
134	Knowns and unknowns in the future of multiple sclerosis treatment. Journal of the Neurological Sciences, 2009, 287, S30-S36.	0.6	14
135	Genetic Polymorphism at Codon 129 of the Prion Protein Gene Is Not Associated With Multiple Sclerosis. Archives of Neurology, 2009, 66, 280-1.	4.5	4
136	PEG Minocycline-Liposomes Ameliorate CNS Autoimmune Disease. PLoS ONE, 2009, 4, e4151.	2.5	41
137	Immunomodulatory treatment strategies in multiple sclerosis. Journal of Neurology, 2008, 255, 15-21.	3.6	27
138	Î±4-Integrin antagonism with natalizumab. Journal of Neurology, 2008, 255, 58-65.	3.6	74
139	Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurology, The, 2008, 7, 173-183.	10.2	70
140	The effects of natalizumab on the innate and adaptive immune system in the central nervous system. Journal of the Neurological Sciences, 2008, 274, 39-41.	0.6	36
141	Pharmacological Treatment of Early Multiple Sclerosis. Drugs, 2008, 68, 73-83.	10.9	41
142	Disease-Modifying Agents for Multiple Sclerosis. Drugs, 2008, 68, 2445-2468.	10.9	63
143	DNA-based vaccines: the future of multiple sclerosis therapy?. Expert Review of Neurotherapeutics, 2008, 8, 351-360.	2.8	11
144	Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab. Archives of Neurology, 2008, 65, 1596.	4.5	179

#	Article	IF	Citations
145	Natalizumab: increased vigilance is required in treating patients with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2008, 1, 155-156.	3.5	2
146	Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients. PLoS ONE, 2008, 3, e2028.	2.5	51
147	Revised criteria for neuromyelitis opticaâ€"a new diagnostic standard?. Nature Clinical Practice Neurology, 2007, 3, 132-133.	2.5	7
148	Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy. Archives of Neurology, 2007, 64, 169.	4.5	65
149	High Incidence of Postâ€"Lumbar Puncture Headaches in Patients With Multiple Sclerosis Treated With Natalizumab: Role of Intrathecal Leukocytes. Archives of Neurology, 2007, 64, 1055.	4.5	2
150	Corticosteroids for Multiple Sclerosis: I. Application for Treating Exacerbations. Neurotherapeutics, 2007, 4, 618-626.	4.4	52
151	Type II monocytes modulate T cellâ€"mediated central nervous system autoimmune disease. Nature Medicine, 2007, 13, 935-943.	30.7	407
152	Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (TysabriÂ®) in Inflammatory Diseases. CNS Neuroscience & Therapeutics, 2007, 13, 79-95.	4.0	98
153	Multiple sclerosis therapy: An update on recently finished trials. Journal of Neurology, 2007, 254, 1473-1490.	3.6	11
154	Central nervous system infections â€" a potential complication of systemic immunotherapy. Current Opinion in Neurology, 2006, 19, 271-276.	3.6	22
155	Optical coherence tomography in multiple sclerosis. Lancet Neurology, The, 2006, 5, 853-863.	10.2	165
156	Statins in the treatment of central nervous system autoimmune disease. Journal of Neuroimmunology, 2006, 178, 140-148.	2.3	59
157	Immune surveillance in multiple sclerosis patients treated with natalizumab. Annals of Neurology, 2006, 59, 743-747.	5.3	414
158	Plasma Exchange in Neuroimmunological Disorders. Archives of Neurology, 2006, 63, 1066.	4.5	71
159	Inhibition by Mitoxantrone of In Vitro Migration of Immunocompetent Cells. Archives of Neurology, 2006, 63, 1572.	4.5	43
160	Plasma Exchange in Neuroimmunological Disorders. Archives of Neurology, 2006, 63, 930.	4.5	130
161	Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. Archives of Neurology, 2006, 63, 1383.	4.5	271
162	Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. Journal of Clinical Investigation, 2006, 116, 1037-1044.	8.2	98

#	Article	IF	Citations
163	Statins â€" a cure-all for the brain?. Nature Reviews Neuroscience, 2005, 6, 325-331.	10.2	104
164	Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurology, The, 2005, 4, 403-412.	10.2	77
165	Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. Journal of Neuroimmunology, 2005, 168, 128-137.	2.3	60
166	Clinical Stabilization and Effective B-Lymphocyte Depletion in the Cerebrospinal Fluid and Peripheral Blood of a Patient With Fulminant Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2005, 62, 1620-3.	4.5	124
167	Therapeutic Potential of Small Interfering RNA for Central Nervous System Diseases. Archives of Neurology, 2005, 62, 1810.	4.5	16
168	Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, S58-S61.	3.0	18
169	Are statins a treatment option for multiple sclerosis?. Lancet Neurology, The, 2004, 3, 369-371.	10.2	77
170	Statins and their potential targets in multiple sclerosis therapy. Expert Opinion on Therapeutic Targets, 2003, 7, 613-622.	3.4	20
171	Statins as potential therapeutic agents in neuroinflammatory disorders. Current Opinion in Neurology, 2003, 16, 393-401.	3.6	97
172	Statins as potential therapeutic agents in neuroinflammatory disorders. Current Opinion in Neurology, 2003, 16, 393-401.	3.6	78
173	Approved and Future Pharmacotherapy for Multiple Sclerosis. Neurologist, 2002, 8, 290-301.	0.7	15
174	The Role of the MHC Class II Transactivator in Class II Expression and Antigen Presentation by Astrocytes and in Susceptibility to Central Nervous System Autoimmune Disease. Journal of Immunology, 2002, 169, 6720-6732.	0.8	83
175	The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 2002, 420, 78-84.	27.8	1,060
176	Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-Î³-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4+T-cell activation. Glia, 2001, 36, 391-405.	4.9	46
177	Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity. Journal of Clinical Investigation, 2001, 108, 1133-1139.	8.2	78
178	Migratory behavior of lymphocytes isolated from multiple sclerosis patients: Effects of interferon ?-1b therapy. Annals of Neurology, 1999, 46, 319-324.	5.3	66
179	Interferon beta in the treatment of multiple sclerosis. Neurology, 1998, 51, 682-689.	1.1	344
180	Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. Journal of Neuroimmunology, 1997, 80, 38-46.	2.3	102

#	Article	IF	Citations
181	Interferon Î²-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9. Annals of Neurology, 1996, 40, 853-863.	5.3	338